A Phase IIa, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller
Latest Information Update: 14 Sep 2023
At a glance
- Drugs RG-6173 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Genentech
Most Recent Events
- 19 Dec 2022 This trial has been completed in Poland (End Date: 19 May 2022) according to European Clinical Trials Database record.
- 25 May 2022 Status changed from active, no longer recruiting to completed.
- 18 Jan 2022 Planned End Date changed from 14 Sep 2022 to 21 May 2022.